IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

被引：0

作者：

Trojan, J. ^{[1
]}

Chow, P. ^{[2
,3
]}

Chen, M. ^{[4
]}

Cheng, A-L ^{[5
,6
]}

Kaseb, A. ^{[7
]}

Kudo, M. ^{[8
]}

Lee, H. C. ^{[9
]}

Yopp, A. ^{[10
]}

Zhou, J. ^{[11
]}

Wang, L. ^{[12
]}

Wen, X. ^{[13
]}

Heo, J. ^{[14
,15
]}

Tak, W-Y ^{[16
]}

Nakamura, S. ^{[17
]}

Numata, K. ^{[18
]}

Uguen, T. ^{[19
]}

Hsieh, D. ^{[10
]}

Cha, E. ^{[20
]}

Hack, S. P. ^{[20
]}

Lian, Q. ^{[20
]}

Spahn, J. ^{[20
]}

Wu, C. ^{[21
]}

Qin, S. ^{[22
]}

机构：

[1] Univ Klinikum Frankfurt, Frankfurt, Germany

[2] Natl Canc Ctr Singapore, Singapur, Singapore

[3] Duke NUS Med Sch, Singapur, Singapore

[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[5] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Kindai Univ, Osaka, Japan

[9] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[10] UT Southwestern Med Ctr, Dallas, TX USA

[11] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] 1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China

[14] Pusan Natl Univ, Coll Med, Busan, South Korea

[15] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea

[16] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea

[17] Himeji Red Cross Hosp, Himeji, Hyogo, Japan

[18] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan

[19] Hosp Pontchaillou, Rennes, France

[20] Genentech Inc, San Francisco, CA USA

[21] Roche Holding Ltd, Shanghai, Peoples R China

[22] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P687

引用

页码：239 / 239

页数：1

共 50 条

[41] Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection
Chen, Yiwen
Shen, Yan
Zhang, Min
Wu, Jian
Gao, Shunliang
Que, Risheng
Yu, Jun
Tang, Xiaofeng
Bai, Xueli
Liang, Tingbo
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 571 - 571
[42] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
Ducreux, Michel
Zhu, Andrew X.
Cheng, Ann-Lii
Galle, Peter R.
Ikeda, Masafumi
Nicholas, Alan
Verret, Wendy
Li, Lindong
Gaillard, Vincent E.
Lencioni, Riccardo
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Nishikawa, Hiroki
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Koshiyama, Yuichi
Toyoda, Hidenori
Ogawa, Chikara
Hatanaka, Takeshi
Kakizaki, Satoru
Kawata, Kazuhito
Ohama, Hideko
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Nishimura, Takashi
Imai, Michitaka
Kosaka, Hisashi
Naganuma, Atsushi
Matono, Tomomitsu
Aoki, Tomoko
Kuroda, Hidekatsu
Yata, Yutaka
Koizumi, Yohei
Nakamura, Shinichiro
Enomoto, Hirayuki
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 233 - 245
[44] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Galle, P.
Finn, R. S.
Qin, S.
Ikeda, M.
Ducreux, M.
Kim, T. -Y
Lim, H. Y.
Kudo, M.
Breder, V
Merle, P.
Kaseb, A.
Li, D.
Verret, W.
Shao, H.
Liu, J.
Li, L.
Zhu, A. X.
Cheng, A. -L
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
[45] Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence
Liao, Yadi
Zheng, Yun
He, Wei
Li, Qijiong
Shen, Jingxian
Hong, Jian
Zou, Ruhai
Qiu, Jiliang
Li, Binkui
Yuan, Yunfei
ONCOLOGY LETTERS, 2017, 13 (02) : 984 - 992
[46] Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study
Kato, Daisuke
Suzuki, Takanori
Matsuura, Kentaro
Okayama, Kohei
Okumura, Fumihiro
Nagura, Yoshihito
Sobue, Satoshi
Hayashi, Katsumi
Kusakabe, Atsunori
Hasegawa, Izumi
Matoya, Sho
Mizoshita, Tsutomu
Kimura, Yoshihide
Kondo, Hiromu
Ozasa, Atsushi
Kawamura, Hayato
Fujiwara, Kei
Nojiri, Shunsuke
Kataoka, Hiromi
ONCOLOGY, 2024,
[47] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
Kudo, Masatoshi
Finn, Richard S. S.
Galle, Peter R. R.
Zhu, Andrew X. X.
Ducreux, Michel
Cheng, Ann-Lii
Ikeda, Masafumi
Tsuchiya, Kaoru
Aoki, Ken-ichi
Jia, Jing
Lencioni, Riccardo
LIVER CANCER, 2023, 12 (03) : 238 - 250
[48] The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.
Zhu, Xiao-Dong
Sun, Hui-Chuan
Shen, Feng
Bai, Xueli
Chen, Minshan
Huang, Zhiyong
Song, Tianqiang
Zeng, Yongyi
Kuang, Ming
Xiang, Bangde
Liu, Lianxin
Li, Deyu
Wen, Tianfu
Chen, Yongjun
Peng, Tao
Li, Xiangcheng
Zhou, Jian
Fan, Jia
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
Duan, Xiaohui
Wu, Dongde
Zhou, Cuncai
Tian, Yifeng
Shen, Jian
Xu, Guohui
Bai, Yannan
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 601 - 601
[50] Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
Su, Jia-Yong
Liu, Shao-Ping
Xu, Xiao-Ling
Ou, Jun-Jie
Ye, Po-Hua
Zhao, Bin-Tong
Chen, Jia-Song
Luo, Qiu-Mei
Liu, Jin-Rong
Tang, Fei-Min
Li, Jian-Rong
Yang, Da-Long
Deng, Zhu-Jian
Pan, Li-Xin
Li, Yao-Jie
Li, Le
Qin, Zhen-Ming
Liang, Xiu-Mei
Ma, Yi-Li
Ma, Liang
Zhong, Jian-Hong
LIVER CANCER, 2024,

← 1 2 3 4 5 →